Based on the negative role of FoxO-1 in insulin action, FoxO-1 inhibitors may be applicable as a new therapeutic approach to treat metabolic disorders, including type 2 diabetes. The gene discussed is FOXO1; the disease is type 2 diabetes mellitus.